2026 FDA Workshop on Bayesian Methods in Clinical Trials

The 2026 FDA Workshop on Bayesian Methods in Clinical Trials is a specialized event organized by the U.S. Food and Drug Administration (FDA). This workshop aims to provide a comprehensive understanding of Bayesian statistical methodologies and their application in the design and analysis of clinical trials for drugs and biological products.

Key topics covered in the workshop include the integration of prior information into current trial data, adaptive trial designs, and the use of Bayesian methods to enhance decision-making processes. Sessions will delve into practical aspects such as determining futility or success earlier in adaptive trials, informing design elements like dose selection, and incorporating information from previous clinical studies or real-world evidence.

Attendees will have opportunities to engage in networking sessions, participate in panel discussions with FDA statisticians and industry experts, and explore case studies demonstrating successful implementation of Bayesian approaches in clinical trials. Notable speakers will include leading statisticians and regulatory professionals specializing in innovative trial designs.

This workshop is ideal for clinical researchers, biostatisticians, regulatory affairs professionals, and pharmaceutical industry stakeholders interested in modernizing clinical trial methodologies. Participants will gain valuable insights into the FDA's perspective on Bayesian methods and learn how to apply these approaches to improve trial efficiency and effectiveness.